RVL Pharmaceuticals Future Growth
Future criteria checks 2/6
RVL Pharmaceuticals is forecast to grow earnings and revenue by 32.8% and 32.7% per annum respectively while EPS is expected to grow by 34.9% per annum.
Key information
32.8%
Earnings growth rate
34.9%
EPS growth rate
Pharmaceuticals earnings growth | 22.4% |
Revenue growth rate | 32.7% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 27 Oct 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 76 | -27 | N/A | N/A | 1 |
12/31/2024 | 53 | -43 | N/A | N/A | 1 |
12/31/2023 | 36 | -58 | N/A | N/A | 1 |
6/30/2023 | 37 | -68 | -47 | -44 | N/A |
3/31/2023 | 37 | -56 | -32 | -30 | N/A |
12/31/2022 | 50 | -52 | -39 | -38 | N/A |
9/30/2022 | 43 | -53 | -46 | -46 | N/A |
6/30/2022 | 35 | -66 | -52 | -52 | N/A |
3/31/2022 | 38 | -76 | -58 | -57 | N/A |
12/31/2021 | 18 | -83 | -49 | -55 | N/A |
9/30/2021 | 16 | -115 | -34 | -39 | N/A |
6/30/2021 | 40 | -86 | -9 | -13 | N/A |
3/31/2021 | 28 | -82 | 11 | 6 | N/A |
12/31/2020 | 28 | -89 | 15 | 18 | N/A |
9/30/2020 | 87 | -64 | 23 | 27 | N/A |
6/30/2020 | 126 | -178 | 51 | 54 | N/A |
3/31/2020 | 183 | -285 | 35 | 40 | N/A |
12/31/2019 | 240 | -271 | 30 | 34 | N/A |
9/30/2019 | 246 | -351 | 59 | 63 | N/A |
6/30/2019 | 247 | -243 | 29 | 33 | N/A |
3/31/2019 | 261 | -112 | 21 | 24 | N/A |
12/31/2018 | 264 | -110 | 33 | 38 | N/A |
9/30/2018 | 274 | -1 | 14 | 29 | N/A |
6/30/2018 | 262 | -10 | 3 | 19 | N/A |
3/31/2018 | 248 | -31 | 27 | 45 | N/A |
12/31/2017 | 246 | -41 | 38 | 58 | N/A |
12/31/2016 | 218 | -42 | N/A | -45 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: O1P is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: O1P is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: O1P is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: O1P's revenue (32.7% per year) is forecast to grow faster than the German market (4.4% per year).
High Growth Revenue: O1P's revenue (32.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if O1P's Return on Equity is forecast to be high in 3 years time